Streetbeat News

Regulatory

MTEK

Maris-Tech has been granted a U.S. patent for a new forward error correction optimization method that reduces overhead data in media streaming. This innovation could enhance the efficiency of media communication.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:52 am

PROK

ProKidney is prioritizing its PROACT 1 trial and discontinuing PROACT 2, which was focused on non-U.S. enrollment. This decision is expected to extend their cash runway to Q1 2027 and reduce expenses by $150-$175 million. The company anticipates FDA approval for rilparencel through an expedited pathway.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:39 am

SNGX

Soligenix has been granted a European patent for 'Systems and Methods for Producing Synthetic Hypericin', which could enhance its intellectual property portfolio and potentially boost its market position.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:35 am

IVVD

Invivyd reports that their product PEMGARDA™ (pemivibart) continues to show neutralizing effects against dominant SARS-CoV-2 variants, including KP.3.1.1 and LB.1. The CDC notes KP.3.1.1 is the only major variant increasing nationally. Data has been submitted to the FDA for updates to the PEMGARDA™ Fact Sheet.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:29 am

AZN

AstraZeneca is set to present over 130 abstracts at the IASLC 2024 World Conference on Lung Cancer and the ESMO Congress, showcasing 17 approved and potential new medicines. This includes five Presidential Symposia and 41 oral presentations.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:26 am

EADSY

Cathay Pacific has identified 15 Airbus A350 planes needing engine part replacements after an inspection following an engine component failure on a flight. The airline has already repaired three of the affected planes and expects all to be operational by Saturday. The issue led to the cancellation of 34 flights, but other airlines with similar planes have not been instructed to inspect their fleets.

Portfolio Pulse from Anan Ashraf

September 03, 2024 | 11:19 am

PCVX

Vaxcyte announced positive results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The vaccine showed strong immune responses and a good safety profile, meeting regulatory criteria. Vaxcyte plans to advance to Phase 3 trials for adults and initiate a Phase 2 study for infants.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:12 am

UNCY

Unicycive Therapeutics has submitted a New Drug Application to the FDA for Oxylanthanum Carbonate, targeting hyperphosphatemia in chronic kidney disease patients on dialysis. The company is seeking approval through the 505(B)(2) regulatory pathway.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:06 am

RNAC

Cartesian Therapeutics has initiated a Phase 1 trial for Descartes-15, an mRNA-engineered CAR T-cell therapy targeting multiple myeloma. The trial will evaluate safety and tolerability, with future plans to explore autoimmune applications.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:04 am

BITF

RIOT

Riot Platforms, Inc. (NASDAQ:RIOT) is pushing for changes in Bitfarms Ltd.'s board due to governance issues. Riot, owning 19.9% of Bitfarms, criticizes recent board changes and the proposed acquisition of Stronghold Digital Mining, citing concerns over governance and shareholder interests.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 10:50 am